---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-226999"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2024-09-26T23:59:59+00:00"
generated_at: "2026-05-31T01:39:07.499215+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma FY2024 net loss $22.4M, cash $50.9M; BB-301 shows swallowing improvement

## Summary
- Net loss of $22.4M ($5.51 per share) for FY2024; cash and equivalents $50.9M as of June 30, 2024.
- Oversubscribed $40M PIPE closed April 2024; cash runway extended through 2025.
- Interim data for first low-dose BB-301 subject showed clinically meaningful improvements in swallowing at 90 and 180 days; no SAEs.
- Second subject dosed Feb 2024; third subject expected Q4 2024.
- Kishen Mehta appointed to board effective June 26, 2024.

## SEC filing metadata
- accession: 0001193125-24-226999
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2024-09-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312524226999/0001193125-24-226999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312524226999/d817476d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-226999
- JSON: https://secwatch.observer/filing/0001193125-24-226999.json
- Plain text: https://secwatch.observer/filing/0001193125-24-226999.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.